IMC Chicago’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.1M Sell
98,800
-5,400
-5% -$819K ﹤0.01% 1387
2026
Q2
$16.3M Buy
104,200
+49,700
+91% +$7.45M ﹤0.01% 1202
2026
Q1
$8.32M Sell
54,500
-7,000
-11% -$1.07M ﹤0.01% 1417
2025
Q4
$8.48M Buy
61,500
+26,300
+75% +$3.44M ﹤0.01% 1355
2025
Q3
$4.51M Buy
35,200
+3,400
+11% +$415K ﹤0.01% 1641
2025
Q2
$3.85M Sell
31,800
-7,400
-19% -$834K ﹤0.01% 1564
2025
Q1
$4.37M Buy
39,200
+12,200
+45% +$1.3M ﹤0.01% 1306
2024
Q4
$2.63M Buy
27,000
+3,900
+17% +$416K ﹤0.01% 1669
2024
Q3
$2.66M Sell
23,100
-100
-0.4% -$11.3K ﹤0.01% 1495
2024
Q2
$2.47M Sell
23,200
-700
-3% -$70.3K ﹤0.01% 1442
2024
Q1
$2.31M Buy
+23,900
New +$2.45M ﹤0.01% 1291

Other funds holding NVS

IMC Chicago's NVS Position: Q3 2026 in Review

IMC Chicago sold out of Novartis (NVS) in Q3 2026, closing a stake of 9,740 shares — an estimated $1.48M sold.

IMC Chicago first reported a position in NVS in Q2 2026 and held it in 1 quarter. The position peaked at $1.53M in Q2 2026. 1,557 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • IMC Chicago reported no remaining Novartis position as of Q3 2026 after selling out during the quarter.
  • IMC Chicago sold 9,740 Novartis shares in Q3 2026, an estimated $1.48M.
  • IMC Chicago first reported a position in Novartis in Q2 2026 and held it in 1 quarter.
  • IMC Chicago's Novartis position peaked at $1.53M in Q2 2026.
  • 1,557 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.